Attention www.globalkeysolutions.net is now www.keypedia.com, read the full press release here.
KeyPedia LogoKeyPedia Icon
  1. Home
  2. /
  3. Records
  4. /
  5. Warning Letter
  6. /
  7. Triangle Compounding
WARNING LETTER
•Triangle Compounding•March 1, 2013

Triangle Compounding – FDA Warning Letter, Mar 1, 2013

Record Details

From February 19 to March 1, 2013, an FDA inspection of Triangle Compounding Pharmacy identified serious deficiencies. The firm was producing drug products without valid prescriptions for individually-identified patients, violating Section 503A of the FDCA and rendering these drugs unapproved new drugs and misbranded under Sections 505(a) and 502(f)(1) of the FDCA.

Furthermore, the inspection revealed insanitary conditions in sterile drug production, causing all sterile products to be adulterated per Section 501(a)(2)(A) of the FDCA. Specific issues included a (b)(4) hood near a window with blinds, a non-cleanable wall surface with a ledge, and an operator shaking the hood during aseptic filling. The firm also improperly invalidated a failed sterility test result for a batch.

For drugs compounded without individual prescriptions, the firm is subject to CGMP regulations (21 CFR Parts 210 and 211), and significant violations were observed, leading to adulteration under Section 501(a)(2)(B). These violations included failure to investigate discrepancies (21 CFR 211.192), inadequate stability testing (21 CFR 211.166(a)), insufficient procedures to prevent microbiological contamination (21 CFR 211.113(b)), inadequate equipment maintenance for aseptic conditions (

Company
Triangle Compounding
Inspection date
March 1, 2013
Product type
Drugs
Office
Atlanta District Office
People
  • Ingrid A. Zambrana
  • Marie Mathews
View Company Profile

ID · 34b65abd-c223-45dd-80d6-cfc6c589a853

Violation Codes10
21 U.S.C. 353a21.U.S.C. 355(a)21 U.S.C. 352(f)(1)21 U.S.C. 351(a)(2)(A)21 U.S.C. 331(d)21 U.S.C. 331(k)21 CFR 211.19221 CFR 211.166(a)21 CFR 211.113(b)21 CFR 211.42(c)(10)(vi)

Full citation text and observation details available on the Dashboard.

Other documents for Triangle Compounding
  • WARNING_LETTER - 2015-01-16January 16, 2015

Your cart

Your cart is empty.

Browse public document pages and click Buy this document. We'll ask for your email at checkout, no account needed up front.

Browse documents

Discuss this record with AI

KeyPedia

ChatGPT

Claude

Perplexity

Grok

Copilot

Document or profile

One record shows the event. A profile shows the pattern.

Buy this document for the source file and details behind this single event.

Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.

Explore Triangle Compounding
KeyPedia
Regulatory Data Transformed
Stay in the loop

KRA score changes, company updates and news. About monthly, unsubscribe anytime.

Contact
New York Office:
370 Jay Street 7th Floor
Brooklyn, NY 11201
Scranton Office:
Scranton Enterprise Center, Suite 217
201 Lackawanna Avenue
Scranton, PA, 18503
🇺🇸+1 917-789-5099
🇪🇺+48 532-447-507
info@keypedia.com
Quick Links
HomePlatform OverviewMedia
KeyPedia™ Lite
Browse HubDatabase DirectoryRecordsCompaniesOfficesPeopleCareersAbout UsFounding TeamMeet Our ExpertsPartners
Legal & Ethics
Privacy PolicyTerms of ServiceOur Values & MissionCode of Ethics & AI Policy
©2026 KeyPedia™ | Global Key Solutions Corp. All rights reserved.